MMJ's DEA lawsuit continues moving through the federal courts. The 8 organizations who have been issued DEA federal cannabis registrations since 2021, all are incapable of growing pharmaceutical-grade marijuana and 7 are now either inactive or bankrupt.
Read MoreCrofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program
Read MoreThe statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium
Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
Read More- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -
- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -
- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne -
Read MorePrivate Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies
US$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headache
Lobe creates Cynaptec Pharmaceuticals, Inc. which will own and develop Conjugated Psilocin TM
Plans to conduct consumer and safety testing during second quarter 2025
Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production
Single dose pre-workout supplement expected to be available in at least three flavors and launch in specialty retailers of nutritional products in 2025
Read More
Survey of 1,672 healthcare providers and 200 healthcare consumers reveals aligned and divergent perspectives on digital tools, engagement barriers, and strategies driving success in 2025
Read More84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously
Read More
"MMJ BioPharma Cultivation is engaged not only in a fight for justice but for the integrity of our legal system. As we stand against the DEA's disregard for Supreme Court directives, we are not merely defending our rights; we are upholding the principle that the DEA should not be above the law, especially not one that regulates medical progress. This isn't just our battle-it's a stand for every American whose life and liberties depend on the fair application of justice." - Duane Boise, CEO of MMJ BioPharma Cultivation
Read MoreOne clinical trial site activated
Patient enrollment expected in April
Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product
Aspire anticipates releasing initial clinical data from trial at the end of the second quarter
Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product
